American Sentinel University was a for-profit university, offering distance-learning healthcare focused degrees and certificate programs. American Sentinel University is regionally accredited by the Higher Learning Commission (HLC) and nationally accredited by the Distance Education Accrediting Commission (DEAC).In February 2021 it was announced that American Sentinel University was to be acquired by Post University. The acquisition was completed in March 2021.
Cloud computing has revolutionized the way organizations manage their IT infrastructure, but it has also introduced new challenges, such as managing cloud costs. This paper explores various techniques for cloud cost optimization, including cloud pricing, analysis, and strategies for resource allocation. Real-world case studies of these techniques are presented, along with a discussion of their effectiveness and key takeaways. The analysis conducted in this paper reveals that organizations can achieve significant cost savings by adopting cloud cost optimization techniques. Additionally, future research directions are proposed to advance the state of the art in this important field.
Fusobacterium varium has been generally overlooked in cattle rumen microbiome studies relative to the presumably more abundant liver abscess-causing Fusobacterium necrophorum. However, F. varium was found to be more abundant in the rumen fluid of cattle and under culture conditions tailored to enrich F. necrophorum. Using near-full length 16S ribosomal ribonucleic acid sequencing, we demonstrate that F. varium grows under restrictive conditions commonly used to enumerate F. necrophorum, suggesting that previous F. necrophorum abundance assessment may have been inaccurate and that F. varium may be an underestimated member of the ruminal bacterial community. Fusobacterium varium were not as susceptible as F. necrophorum to in-feed antibiotics conventionally used in feedlots. Exposure to tylosin, the current gold standard for liver abscess reduction strategies in cattle, consistently hindered growth of the F. necrophorum strains tested by over 67% (P < 0.05) relative to the unexposed control. In contrast, F. varium strains were totally or highly resistant (0%–13% reduction in maximum yield, P < 0.05). Monensin, an ionophore antibiotic, had greater inhibitory activity against F. necrophorum than F. varium. Finally, preliminary genomic analysis of two F. varium isolates from the rumen revealed the presence of virulence genes related to those of pathogenic human F. varium isolates associated with active invasion of mammalian cells. The data presented here encourage further investigation into the ecological role of F. varium within the bovine rumen and potential role in liver abscess development, and proactive interventions.
Recycling and waste management have garnered immense popularity in recent years, but few studies have been carried out regarding these systems. Therefore, an in-depth literature review was done in order to highlight the different sectors of the recycling system that need to be reformed. Hence this study examined recycling and waste management systems within three categories–medical, municipal, and plastic–that were carried out pre and post COVID by reviewing previous studies, technical reports, and annual reports. This was done by visiting numerous academic search engines alongside online resources that were utilized to assemble literature related to waste and recycling systems. Continuing a recurring idea was that no matter the type of waste, further research regarding all waste should be carried out. Additionally, since recycling and waste management are a vital part of our society, and seeing how unpredictable events such as the pandemic may be, it is paramount that that research is done not only on how the pandemic has affected systems now, but also how we can learn from current issues to utilize them for future “waste shocks”.
Dear Editor, Children are a vulnerable population when it comes to TB, including rifampicin-resistant forms of the disease (RR-TB).1 Although the largest challenge facing children with RR-TB is being diagnosed and started on appropriate treatment, they also face a difficult treatment journey.2 Children with RR-TB are reported to have excellent treatment outcomes,3 but treatment is characterized by highly centralized services and limited pediatric formulations of second-line drugs.4 This complicates the care of very young children, as adult tablets need to be cut, crushed and mixed prior to administration. These manipulations often require hospitalization for the duration of therapy, with all the related difficulties for young patients and their families.5 Delamanid (DLM) is a newer, nitroimidazole agent developed for the treatment of RR-TB and first recommended by the WHO in 2013.6 The medication development plan included a robust pediatric component, and thus DLM was the first novel TB drug specifically recommended for children as part of all-oral therapy.7 Concerns about manipulating the adult tablet led to impractical recommendations regarding DLM use in young children, in which the drug was theoretically recommended but the weight-based dosing could not be achieved with the adult formulation.8 The 25 mg pediatric formulation of DLM that was tested in randomized clinical trials has only recently became available, and experience with its use under program conditions is limited. We report here on a cohort of eight children who received treatment with the new pediatric formulation of DLM as part of a community-based program in the peri-urban township of Khayelitsha in Cape Town, South Africa. Khayelitsha is home to about 500,000 individuals and is a high-burden HIV and RR-TB setting, with approximately 200 individuals diagnosed with RR-TB each year. Since 2019, the Departments of Health from the Province of the Western Cape and the City of Cape Town have been working in partnership with Médecins Sans Frontières (MSF) to provide community-based diagnostic, preventive and treatment services to children exposed to RR-TB.9 As part of this program, children diagnosed with RR-TB are treated through one of 10 primary care clinics in the catchment area if they are clinically stable, or they are referred for hospitalization if they have a clinical indication. Children are treated with all-oral regimens either based on their own drug susceptibility test results or on those of their close household members who were living with RRTB. Regimens are designed following South African national guidelines for the treatment of RR-TB,10 and include a minimum of four anti-TB medications given for a period of 9–18 months, depending on disease severity. Children between the ages of 3 and 6 years were preferentially treated with DLM using weightbased dosing. The pediatric formulation for DLM was obtained through a named-patient-basis administered by Otsuka Pharma, Tokyo, Japan (for more information on this program, please contact medical@otsuka-onpg.com). Children in need of the pediatric formulation of DLM (a 25 mg, dispersible, mango-flavored tablet) were assessed by the medical team in Khayelitsha and then reviewed by a team of external clinical experts at the Sentinel Project on Pediatric Drug-Resistant Tuberculosis.11 Following this, a regimen was proposed and a formal application submitted to Otsuka for the pediatric formulation. Approval to import the medication was obtained via the South Africa Health Products Regulatory Authority using their section 21 mechanism (https://s21portal.sahpra.org.za/). DLM was administered as part of a combination regimen usually for 24 weeks. Weight-based dosing was used for all components of the regimen, including DLM, following South African guidelines. Caregivers prepared and administered all the medication after counseling by healthcare providers. This study was approved by the University of Cape Town Human Research Ethics Committee, Cape Town, South Africa (HREC 499/2011). Between February 1, 2021 and February 28, 2022, eight children aged 6 years were deemed eligible for treatment with the pediatric formulation of DLM. Applications were submitted for all eight children, and all were approved for pediatric DLM. The turnaround time for submission of the applications to Otsuka was less than 2 weeks, and the medications were shipped and arrived for treatment in Khayelitsha within 10 days of approval. Thus, the overall turnaround time from application to receipt of the medication was less than 4 weeks. While awaiting the medication, adult tablets of DLM were given in the primary care clinics. At the time of writing, four of
